Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 11/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21524552 | 0.89 | TMEM97 (0.49) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257170 | 0.89 | TMEM97 (0.51) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257165 | 0.88 | ALDH1A1 (0.48) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257200 | 0.85 | HTT (0.49) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257236 | 0.84 | HTT (0.63) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257169 | 0.84 | HTT (0.63) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257168 | 0.82 | TMEM97 (0.68) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257212 | 0.80 | ALDH1A1 (0.69) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18249549 | 0.79 | HTT (0.55) | TMEM97SIGMAR1HTTALDH1A1HPGD | |
| SCHEMBL18257163 | 0.78 | ALDH1A1 (0.55) | TMEM97SIGMAR1HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457662-B2 | Substituted amides for treating and preventing cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2016187544-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457662-B2 | Substituted amides for treating and preventing cancer | NQO1, NNT, SIRT1 | TMEM97 4292/4885SIGMAR1 3919/4885HTT 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.